

**PCT**

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



B<sup>21</sup>

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b> <b>A61K 37/16, 39/00, C12P 21/02</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 94/02167</b> <b>(43) International Publication Date:</b> 3 February 1994 (03.02.94)
<b>(21) International Application Number:</b> PCT/US93/07069 <b>(22) International Filing Date:</b> 22 July 1993 (22.07.93)  <b>(30) Priority data:</b> 07/918,292 22 July 1992 (22.07.92) US 08/015,493 9 February 1993 (09.02.93) US  <b>(71) Applicant:</b> THE TRUSTEES OF PRINCETON UNIVERSITY [US/US]; 5 New South Building, Princeton, NJ 08544-0036 (US).  <b>(72) Inventor:</b> LEVINE, Arnold, J. ; 138 Fritzrandolph Road, Princeton, NJ 08540 (US).  <b>(74) Agents:</b> FEIT, Irving, N. et al.; ImClone Systems Incorporated, 180 Varick Street, New York, NY 10014 (US).		<b>(81) Designated States:</b> AU, CA, FI, HU, JP, KR, NO, RO, RU, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> p53 VACCINE  <b>(57) Abstract</b>  The subject invention provides a vaccine composition comprising a mutant or wild-type p53 protein in a form that, when presented to the immune system of a mammal, induces an effective immune response, i.e., either on the surface of an antigen presenting cell or combined with a pharmaceutically acceptable adjuvant. Further, the subject invention provides a method of inhibiting the growth of tumors in mammals comprising treating a mammal with an immunologically effective amount of a vaccine comprising the mutant or wild-type p53 protein.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NE	Niger
BE	Belgium	GN	Guinea	NL	Netherlands
BF	Burkina Faso	GR	Greece	NO	Norway
BG	Bulgaria	HU	Hungary	NZ	New Zealand
BJ	Benin	IE	Ireland	PL	Poland
BR	Brazil	IT	Italy	PT	Portugal
BY	Belarus	JP	Japan	RO	Romania
CA	Canada	KP	Democratic People's Republic of Korea	RU	Russian Federation
CF	Central African Republic	KR	Republic of Korea	SD	Sudan
CG	Congo	KZ	Kazakhstan	SE	Sweden
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovak Republic
CM	Cameroon	LU	Luxembourg	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	MC	Monaco	TG	Togo
CZ	Czech Republic	MG	Madagascar	UA	Ukraine
DE	Germany	ML	Mali	US	United States of America
DK	Denmark	MN	Mongolia	UZ	Uzbekistan
ES	Spain			VN	Viet Nam
FI	Finland				

**p53 Vaccine**

This application is a continuation-in-part of Serial Number 07/918,292 filed July 22, 1992, which is incorporated herein by reference.

5           The present invention is directed to a vaccine for treating cancer. The vaccine comprises a p53 protein as the immunogen.

10           The p53 gene, which is found on chromosome 17p of the human genome, is a tumor suppressor gene in its wild-type state. A review article by Levine et al. entitled "The p53 Tumor Suppressor Gene" appears in Nature 351, 453-456 (1991).

15           More than 50% of human tumors contain cells expressing a mutant form of the p53 gene. In many tumors, one allele of the p53 gene contains a point mutation that encodes a mutant form of the protein while the other allele is partially or totally lost. This pattern is  
20           observed, for example, in approximately 70-80% of colon cancers, 50% of breast cancers, and 50% of lung cancers including 100% of small cell lung cancers. Suggestions have been made to diagnose cancers by detecting the loss of wild type p53 (see Vogelstein et al., European Patent  
25           Application 390,323 and Baker et al., Science 244, 217-221 (1989)).

30           The position or location of the point mutation in the p53 gene differs in different types of tumors. For example, 50% of the hepatocellular carcinomas in humans exposed to hepatitis B and aflatoxin contain p53 mutations

at codon 249; lung tumors appear to contain mutations preferentially at codons 154 and 273; colon tumors have multiple independent mutations at codons 175, 248, and 273. Evidence has been presented that various phenotypes, including the severity and nature of cancer and pre-cancer states, can be distinguished by determining the site of p53 mutations. See Levine et al., International Application No. PCT/US91/04608, filed June 27, 1991.

Approximately 10-20% of humans with cancers have tumors that produce antibodies directed against the p53 protein; de Fromentel et al., International Journal of Cancer 39, 185-189 (1987); Crawford et al., International Journal of Cancer 30, 403-408 (1982). The presence of these antibodies suggests that class II receptors of the human HLA or the murine H-2 locus can present peptide antigens of p53 to the CD-4 helper T-cell and B-cell system, resulting in an immune response. Antibodies are not, however, believed to be effective anti-tumor agents. Therefore, the presence of anti-p53 antibodies in humans with cancer does not suggest the possibility of cancer patients producing an effective anti-tumor immune response.

There are reports that animals immunized with a tumor antigen are protected against the same antigen. Thus, immunizing animals with simian virus 40 (SV40) large T antigen can protect against subsequent challenges with live tumorigenic SV40-transformed cells; see Tevethia et al., Cold Spring Harbor Symp. Quant. Biol. 44, 235-242 (1980).

Similarly, Frey and Levine have reported that rats immunized with an irradiated p53-plus-ras-transformed

Fisher rat cell line, designated B3, were protected from subsequent tumor challenge with the same live cell. The p53-plus-ras-transformed rat cell lines were reported to express a tumor-specific transplantation rejection antigen that is common to 85% of independently derived p53-plus-ras-transformed cell lines. Frey and Levine presented evidence that the p53 protein is not the tumor-specific transplantation rejection antigen, and does not protect against challenge by B3 cells; see Journal of Virology 63, 5440-5444 (1989).

Current cancer treatments involve cytotoxic agents, such as chemical compounds and radiation, that are insufficiently specific to tumor cells. There is a need for more specific treatments that do not affect normal cells. There is a particular need for cancer treatments that result from stimulating a patient's own immune system.

#### SUMMARY OF THE INVENTION

These and other objects as will be apparent to those having ordinary skill in the art have been met by providing a vaccine composition comprising a mutant or wild-type p53 protein in a form that, when presented to the immune system of a mammal, induces an effective immune response.

The invention further provides a method of inhibiting the growth of tumors in mammals comprising treating a mammal with an immunologically effective amount of a mutant or wild-type p53 protein.

**DETAILED DESCRIPTION OF THE INVENTION**

The subject invention provides a vaccine composition comprising a mutant or wild-type p53 protein in a form that, when presented to the immune system of a mammal, induces an effective immune response. For example, the mutant or wild-type p53 protein may be present on the surface of an antigen presenting cell or liposome, or combined with a pharmaceutically acceptable adjuvant.

For the purposes of the present specification, the term "wild-type p53 protein" means the nucleotide or amino acid sequence reported by Matlashewski et al, EMBO J. 13, 3257-3262 (1984); Zakut-Houri et al, EMBO J. 4, 1251-1255 (1985); and Lamb and Crawford, Mol. Cell. Biol. 5, 1379-1385 (1986). The sequences are available from GenBank. Wild-type p53 includes a proline/arginine polymorphism at amino acid 72 and the corresponding nucleotide polymorphism.

The p53 protein may be mutated. The mutation is preferably at a position that is frequently found to be mutated in tumor cells, and that leads to inactivation of the wild-type p53 gene. The mutations may be either a single substitution or multiple (i.e. 2-20, preferably 2-10, more preferably 2-5) substitutions.

Suitable mutant human p53 genes are described in Levine, A.J. et al., The p53 Tumor Suppressor Gene, Nature 351:453-456 (1991). Most of the point mutations that occur in the p53 gene are missense mutations, giving rise to an altered p53 protein. The majority of mutations are clustered between amino-acid residues 130 and 290, and mostly localized in four "hot spot" regions of the protein, which coincide with the four most highly

conserved regions of the p53 gene; see Nigro et al, Nature 342, 705-708 (1989). The four "hot spot" mutation regions are at codons 132-143; 174-179; 236-248; and 272-281. The frequency and distribution of these hot spots differ among  
5 cancers from different tissue types.

The wild-type p53 gene and protein are known, and may be obtained in natural or recombinant form by known methods. Such methods include isolating the protein  
10 directly from cells; isolating or synthesizing DNA encoding the protein and using the DNA to produce recombinant protein; and synthesizing the protein chemically from individual amino acids. Methods for obtaining the wild-type p53 gene and protein are described  
15 in Matlashewski et al, EMBO J. 13, 3257-3262 (1984); Zakut-Houri et al, EMBO J. 4, 1251-1255 (1985); and Lamb and Crawford, Mol. Cell. Biol. 5, 1379-1385 (1986). Mutants may be prepared from the wild-type p53 gene by site-directed mutagenesis; see, for example, Zoller and  
20 Smith, Nucl. Acids Res. 10, 6487-6500 (1982); Methods in Enzymology 100, 468-500 (1983); and DNA 3, 479-488 (1984).

The entire p53 gene or fragments of the p53 gene may,  
25 for example, be isolated by using the known DNA sequence to construct oligonucleotide probes. To do so, DNA restriction fragments are identified by Southern hybridization using labelled oligonucleotide probes derived from the known sequence.

30 Alternatively, p53-encoding DNA may be synthesized from individual nucleotides. Known methods for synthesizing DNA include preparing overlapping double-stranded oligonucleotides, filling in the gaps, and  
35 ligating the ends together.

The DNA prepared as described above may be amplified by polymerase chain reaction (PCR). Alternatively, the DNA may be amplified by insertion into a cloning vector, which is transfected into a suitable host cell, from which the p53 DNA may be recovered. See, generally, Sambrook et al, "Molecular Cloning," Second Edition, Cold Spring Harbor Laboratory Press (1987).

Recombinant methods well known in the art may be used for preparing the protein. Briefly, p53-encoding DNA is inserted into an expression vector, which is transfected into a suitable host. The DNA is expressed, and the protein is harvested. See Sambrook et al., Id.

Equivalents of the mutant or wild-type p53 protein may also be used in the vaccine of the invention. Such equivalents include analogs that induce an immune response comparable to that of the mutant or wild-type p53 protein. In addition, such equivalents are immunologically cross-reactive with their corresponding mutant or wild-type p53 protein. The equivalent may, for example, be a fragment of the protein, or a substitution, addition or deletion mutant of the mutant or wild-type p53 protein.

The mutant or wild-type p53 protein fragment preferably contains sufficient amino acid residues to define an epitope of the antigen. The fragment may, for example, be a minigene encoding only the epitope. Methods for isolating and identifying immunogenic fragments from known immunogenic proteins are described by Salfeld et al. in J. Virol. 63, 798-808 (1989) and by Isola et al. in J. Virol. 63, 2325-2334 (1989).

If the fragment defines the epitope, but is too short to be immunogenic, it may be conjugated to a carrier



molecule. Some suitable carrier molecules include keyhole limpet hemocyanin, Ig sequences, TrpE, and human or bovine serum albumen. Conjugation may be carried out by methods known in the art. One such method is to combine a  
5 cysteine residue of the fragment with a cysteine residue on the carrier molecule.

Equivalent proteins have equivalent amino acid sequences. An amino acid sequence that is substantially  
10 the same as another sequence, but that differs from the other sequence by one or more substitutions, additions and/or deletions, is considered to be an equivalent sequence. Preferably, less than 25%, more preferably less than 10%, and most preferably less than 5% of the number  
15 of amino acid residues in a sequence are substituted for, added to, or deleted from the proteins of the invention.

For example, it is known to substitute amino acids in a sequence with equivalent amino acids. Groups of amino  
20 acids generally considered to be equivalent are:

- (a) Ala(A) Ser(S) Thr(T) Pro(P) Gly(G);
- (b) Asn(N) Asp(D) Glu(E) Gln(Q);
- (c) His(H) Arg(R) Lys(K);
- 25 (d) Met(M) Leu(L) Ile(I) Val(V); and
- (e) Phe(F) Tyr(Y) Trp(W).

The mutant or wild-type p53 protein of the invention unexpectedly induces an effective immune response when  
30 properly presented to the immune system. For the purposes of this specification, an effective immune response inhibits, i.e. prevents, slows or stops, the growth of cancer cells, or eliminates cancer cells. The effective immune response is preferably a killer T-cell response.  
35 The mammal may be a human or animal typically used for

experimentation, such as mice, rats or rabbits.

5 The mutant or wild-type p53 is presented to the immune system as a vaccine by a vehicle. For example, the mutant or wild-type p53 may be present on the surface of an antigen presenting cell or combined with a pharmaceutically acceptable adjuvant.

10 Antigen presenting cells are generally eukaryotic cells with major histocompatibility complex (MHC), preferably Class II, gene products at their cell surface. For the purposes of this specification, antigen presenting cells also include recombinant eucaryotic cells such as peripheral blood cells and recombinant bacterial cells.  
15 Some examples of antigen presenting cells as defined by this specification include dendritic cells, macrophages that are preferably MHC Class II positive, monocytes that are preferably MHC Class II positive, and lymphocytes.

20 In one embodiment of the subject invention, the antigen presenting cell is a recombinant eucaryotic cell that expresses exogenous DNA encoding mutant or wild-type p53 protein. The recombinant eucaryotic cell may be prepared in vivo or in vitro.

25 In one embodiment, DNA encoding mutant or wild-type p53 is inserted into the eucaryotic cell in vivo using recombinant viral vectors. These vectors include an attenuated recombinant poxvirus, such as vaccinia virus, preferably parrot pox, that has its nonessential virus-  
30 encoded genetic functions inactivated, described in International Application Number PCT/US92/01906, filed March 2, 1992. Techniques for the insertion of foreign DNA into the vaccinia genome are known in the art.  
35 Plasmid vectors for the construction of recombinant

viruses are described in, for example, Chakrabarti et al. (1985) Mol. Cell Biol. 5:3403; Mackett et al., (1984) J. Virol. 49:857; and Moss (1987), page 10 of Gene Transfer Vectors for Mammalian Cells, Miller and Calos, eds., Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.

5 Expression of the mutant or wild-type p53 protein then occurs in vivo in an antigen presenting cell in subjects immunized with the recombinant poxvirus.

10 In another embodiment, DNA encoding mutant or wild-type p53 is inserted into the eucaryotic cell in vitro using known techniques, such as the retroviral transduction techniques described for tumor infiltrating lymphocytes (TILs) (S.A. Rosenberg et al., NEJM, 15 323(9):570-578 (August 30, 1990) and K. Culver et al., PNAS USA 88:3155-3159 (April 1991)).

In another embodiment, minigenes encoding the mutant or wild-type p53 epitope are inserted into the eucaryotic cell in vitro using known techniques (see Hahn et al., 20 Proc. Natl. Acad. Sci. USA 89:2679-2683 (April 1992)).

Suitable cloning/expression vectors for inserting DNA into eucaryotic cells include well-known derivatives of 25 SV-40, adenovirus, cytomegalovirus (CMV), and retrovirus-derived DNA sequences. Any such vectors, when coupled with vectors derived from a combination of plasmids and phage DNA, i.e. shuttle vectors, allow for the cloning and/or expression of protein coding sequences in both 30 procaryotic and eucaryotic cells.

Other eucaryotic expression vectors are known in the art, e.g., P.J. Southern and P. Berg, J. Mol. Appl. Genet. 1, 327-341 (1982); S. Subramani et al, Mol. Cell. Biol. 1, 35 854-864 (1981); R.J. Kaufmann and P.A. Sharp,

"Amplification And Expression Of Sequences Cotransfected with A Modular Dihydrofolate Reductase Complementary DNA Gene," J. Mol. Biol. 159, 601-621 (1982); R.J. Kaufmann and P.A. Sharp, Mol. Cell. Biol. 159, 601-664 (1982); S.I. Scahill et al, "Expression and Characterization of the Product of a Human Immune Interferon DNA Gene in Chinese Hamster Ovary Cells," Proc. Natl. Acad. Sci. USA 80, 4654-4659 (1983); G. Urlaub and L.A. Chasin, Proc. Natl. Acad. Sci. USA 77, 4216-4220, (1980).

The mutant or wild-type p53 protein may also be presented to the immune system on the surface of recombinant bacterial cells. A suitable recombinant bacterial cell is an avirulent strain of Mycobacterium bovis, such as bacille Calmette-Guerin (BCG), or an avirulent strain of Salmonella, such as S. typhimurium. The recombinant bacterial cells may be prepared by cloning DNA comprising the active portion of the p53 protein in an avirulent strain, as is known in the art; see, for example, Curtiss et al., Vaccine 6, 155-160 (1988) and Galan et al., Gene 94, 29-35 (1990) for preparing recombinant Salmonella and Stover, K.S. et al., Vaccines 91, Cold Spring Harbor Laboratory Press, pp. 393-398 (1991) for preparing recombinant BCG.

Cloning vectors may comprise segments of chromosomal, non-chromosomal and synthetic DNA sequences. Some suitable prokaryotic cloning vectors include plasmids from E. coli, such as colE1, pCR1, pBR322, pMB9, pUC, pKSM, and RP4. Prokaryotic vectors also include derivatives of phage DNA such as M13, fd, and other filamentous single-stranded DNA phages.

Vectors for expressing proteins in bacteria, especially E.coli, are also known. Such vectors include

the pK233 (or any of the tac family of plasmids), T7, and  
lambda P<sub>L</sub>. Examples of vectors that express fusion  
proteins are PATH vectors described by Dieckmann and  
Tzagoloff in J. Biol. Chem. 260, 1513-1520 (1985). These  
5 vectors contain DNA sequences that encode anthranilate  
synthetase (TrpE) followed by a polylinker at the carboxy  
terminus. Other expression vector systems are based on  
beta-galactosidase (pEX); lambda P<sub>L</sub>; maltose binding  
protein (pMAL); glutathione S-transferase (pGST) - see  
10 Gene 67, 31 (1988) and Peptide Research 3, 167 (1990).

The expression vectors useful in the present  
invention contain at least one expression control sequence  
that is operatively linked to the DNA sequence or fragment  
15 to be expressed. The control sequence is inserted in the  
vector in order to control and to regulate the expression  
of the cloned DNA sequence. Examples of useful expression  
control sequences are the lac system, the trp system, the  
tac system, the trc system, major operator and promoter  
20 regions of phage lambda, the control region of fd coat  
protein, and promoters derived from polyoma, adenovirus,  
retrovirus, and simian virus, e.g., the early and late  
promoters of SV40, and other sequences known to control  
the expression of genes in prokaryotic or eukaryotic cells  
25 and their viruses or combinations thereof.

The vaccine may further comprise pharmaceutically  
acceptable adjuvants, such as muramyl peptides,  
lymphokines, such as interferon, interleukin-1 and  
30 interleukin-6, or bacterial adjuvants. The adjuvant may  
comprise suitable particles onto which the mutant or wild-  
type p53 protein is adsorbed, such as aluminum oxide  
particles. These vaccine compositions containing  
adjuvants may be prepared as is known in the art.

35

An example of a bacterial adjuvant is BCG. When used as an antigen presenting cell as described above, recombinant BCG may additionally act as its own adjuvant. In this case, additional adjuvant may not be needed although one or more additional adjuvants may optionally be present. When used in its natural (non-recombinant) state, BCG acts solely as an adjuvant by being combined with mutant or wild-type p53, resulting in a form that induces an effective immune response.

The vaccine may also comprise a suitable medium. Suitable media include pharmaceutically acceptable carriers, such as phosphate buffered saline solution, liposomes and emulsions.

The invention further includes a method of inhibiting the growth of tumors in mammals comprising treating a mammal having a tumor or at imminent risk of obtaining a tumor with an immunologically effective amount of a vaccine comprising mutant or wild-type p53. A mammal is at imminent risk of obtaining a tumor if the mammal is diagnosed as having an abnormal, pre-cancerous condition.

The mutant or wild-type p53 is presented to the immune system of the mammal in a form that induces an effective immune response, i.e., either on the surface of an antigen presenting cell or combined with a pharmaceutically acceptable adjuvant. The mutant or wild-type p53 is preferably in a medium such as a pharmaceutically acceptable carrier.

The vaccine may be administered to a mammal by methods known in the art. Such methods include, for example, intravenous, intraperitoneal, subcutaneous, intramuscular, topical, or intradermal administration.

CLAIMS

1. A vaccine composition comprising a mutant p53 protein in a form that, when presented to the immune system of a mammal, induces an effective immune response.
2. A vaccine composition according to claim 1 wherein the composition also comprises a pharmaceutically acceptable medium.
3. A vaccine composition according to claim 1 wherein the form is either the mutant p53 protein on the surface of an antigen presenting cell or the mutant p53 protein combined with a pharmaceutically acceptable adjuvant.
4. A vaccine composition according to claim 3 wherein the form is the mutant p53 protein on the surface of an antigen presenting cell.
5. A vaccine composition according to claim 3 wherein the form is the mutant p53 protein combined with a pharmaceutically acceptable adjuvant.
6. A vaccine composition according to claim 4 wherein the antigen presenting cell is a eucaryotic cell.
7. A vaccine composition according to claim 6 wherein the eucaryotic cell is a dendritic cell, a major histocompatibility complex Class II positive macrophage or a monocyte.

8. A vaccine composition according to claim 7 wherein the antigen presenting cell is a dendritic cell.
9. A vaccine composition according to claim 8 wherein the dendritic cell is a recombinant dendritic cell that expresses exogenous DNA encoding mutant p53 protein on its surface.
10. A vaccine composition according to claim 5 wherein the pharmaceutically acceptable adjuvant is a bacterial cell.
11. A vaccine composition according to claim 10 wherein the bacterial cell is bacille Calmette-Guerin.
12. A vaccine composition according to claim 11 wherein the bacille Calmette-Guerin is a recombinant bacille Calmette-Guerin that expresses exogenous DNA encoding mutant p53 protein.
13. A method of inhibiting the growth of tumors in mammals comprising treating a mammal with an immunologically effective amount of a vaccine composition comprising a mutant p53 protein in a form that, when presented to the immune system of a mammal, induces an effective immune response.
14. The method of claim 13 wherein the vaccine composition also comprises a pharmaceutically acceptable medium.



15. The method of claim 13 wherein the form is either the mutant p53 protein on the surface of an antigen presenting cell or the mutant p53 protein combined with a pharmaceutically acceptable adjuvant.
16. The method according to claim 15 wherein the form is the mutant p53 protein on the surface of an antigen presenting cell.
17. The method according to claim 15 wherein the form is the mutant p53 protein combined with a pharmaceutically acceptable adjuvant.
18. The method of claim 16 wherein the antigen presenting cell is a eucaryotic cell.
19. The method of claim 18 wherein the eucaryotic cell is a dendritic cell, a major histocompatibility complex Class II positive macrophage or a monocyte.
20. The method of claim 19 wherein the antigen presenting cell is a dendritic cell.
21. The method of claim 20 wherein the dendritic cell is a recombinant dendritic cell that expresses exogenous DNA encoding mutant p53 protein.
22. The method of claim 17 wherein the pharmaceutically acceptable adjuvant is a bacterial cell.
23. The method of claim 22 wherein the bacterial

cell is bacille Calmette-Guerin.

24. The method of claim 23 wherein the bacille Calmette-Guerin is a recombinant bacille Calmette-Guerin that expresses exogenous DNA encoding mutant p53 protein.
25. A recombinant antigen presenting cell that expresses exogenous DNA encoding mutant p53 protein.
26. A vaccine composition comprising a wild-type p53 protein in a form that, when presented to the immune system of a mammal, induces an effective immune response.
27. A vaccine composition according to claim 26 wherein the composition also comprises a pharmaceutically acceptable medium.
28. A vaccine composition according to claim 26 wherein the form is either the wild-type p53 protein on the surface of an antigen presenting cell or the wild-type p53 protein combined with a pharmaceutically acceptable adjuvant.
29. A vaccine composition according to claim 28 wherein the form is the wild-type p53 protein on the surface of an antigen presenting cell.
30. A vaccine composition according to claim 28 wherein the form is the wild-type p53 protein combined with a pharmaceutically acceptable adjuvant.

31. A vaccine composition according to claim 29 wherein the antigen presenting cell is a eucaryotic cell.
32. A vaccine composition according to claim 31 wherein the eucaryotic cell is a dendritic cell, a major histocompatibility complex Class II positive macrophage or a monocyte.
33. A vaccine composition according to claim 32 wherein the antigen presenting cell is a dendritic cell.
34. A vaccine composition according to claim 33 wherein the dendritic cell is a recombinant dendritic cell that expresses exogenous DNA encoding wild-type p53 protein on its surface.
35. A vaccine composition according to claim 30 wherein the pharmaceutically acceptable adjuvant is a bacterial cell.
36. A vaccine composition according to claim 35 wherein the bacterial cell is bacille Calmette-Guerin.
37. A vaccine composition according to claim 36 wherein the bacille Calmette-Guerin is a recombinant bacille Calmette-Guerin that expresses exogenous DNA encoding wild-type p53 protein.
38. A method of inhibiting the growth of tumors in mammals comprising treating a mammal with an immunologically effective amount of a vaccine

composition comprising a wild-type p53 protein in a form that, when presented to the immune system of a mammal, induces an effective immune response.

39. The method of claim 38 wherein the vaccine composition also comprises a pharmaceutically acceptable medium.
40. The method of claim 38 wherein the form is either the wild-type p53 protein on the surface of an antigen presenting cell or the wild-type p53 protein combined with a pharmaceutically acceptable adjuvant.
41. The method according to claim 40 wherein the form is the wild-type p53 protein on the surface of an antigen presenting cell.
42. The method according to claim 40 wherein the form is the wild-type p53 protein combined with a pharmaceutically acceptable adjuvant.
43. The method of claim 41 wherein the antigen presenting cell is a eucaryotic cell.
44. The method of claim 43 wherein the eucaryotic cell is a dendritic cell, a major histocompatibility complex Class II positive macrophage or a monocyte.
45. The method of claim 44 wherein the antigen presenting cell is a dendritic cell.
46. The method of claim 45 wherein the dendritic

cell is a recombinant dendritic cell that expresses exogenous DNA encoding wild-type p53 protein.

47. The method of claim 42 wherein the pharmaceutically acceptable adjuvant is a bacterial cell.
48. The method of claim 47 wherein the bacterial cell is bacille Calmette-Guerin.
49. The method of claim 48 wherein the bacille Calmette-Guerin is a recombinant bacille Calmette-Guerin that expresses exogenous DNA encoding wild-type p53 protein.
50. A recombinant antigen presenting cell that expresses exogenous DNA encoding wild-type p53 protein.

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US93/07069**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(5) : A61K 37/16, 39/00; C12P 21/02

US CL : 424/88, 93A, 93B, 93D, 93U, 93V; 435/69.3

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/88, 93A, 93B, 93D, 93U, 93V; 435/69.3

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	NATURE, Volume 351, issued 06 June 1991, A.J. Levine et al, "The p53 Tumour Suppressor Gene", pages 453-456, see entire document.	1-50
Y	NATURE, Volume 351, issued 06 June 1991, C.K. Stover et al, "New Use of BCG for Recombinant Vaccines", pages 456-460, see entire document.	1-5, 10-17, 22-30, 35-42, 47-50
Y	VACCINES 91, issued 1991, C.K. Stover et al, "Development of BCG as a Live Recombinant Vaccine Vehicle", pages 393-398, see entire document.	1-5, 10-17, 22-30, 35-42, 47-50

☒ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* Special categories of cited documents:	
*A* document defining the general state of the art which is not considered to be part of particular relevance	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*E* earlier document published on or after the international filing date	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	*Z* document member of the same patent family

Date of the actual completion of the international search

31 August 1993

Date of mailing of the international search report

14 SEP 1993

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Authorized officer

ANTHONY C. CAPUTA

Facsimile No. NOT APPLICABLE

Telephone No. (703) 308-0196

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US93/07069

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, Volume 87, issued January 1990, A. Kasid et al, "Human Gene Transfer: Characterization of Human Tumor Infiltrating Lymphocytes as Vehicles for Retroviral-Mediated Gene Transfer in Man", pages 473-477, see entire document.	1-6, 13-18, 25-31, 38-43, 50
Y	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, Volume 88, issued April 1991, K. Culver et al, "Lymphocytes as Cellular Vehicles for Gene Therapy in Mouse and Man", pages 3155-3159, see entire document.	1-6, 13-18, 25-31, 38-43, 50
Y	JOURNAL OF EXPERIMENTAL MEDICINE, Volume 169, issued April 1989, S.E. Macatonia et al, "Primary Stimulation by Dendritic Cells Induces Antiviral Proliferative and Cytotoxic T Cell Responses in Vitro", pages 1255-1264, see entire document.	1-9, 13-21, 25-34, 38-46, 50
Y	D.P. STITES et al, "BASIC AND CLINICAL IMMUNOLOGY", published 1991, by APPLETON & LANGE (CONN.), see pages 580-587.	1-50
Y	JOURNAL OF EXPERIMENTAL MEDICINE, Volume 173, issued January 1991, S. Jung et al, "Human T Lymphocyte Recognize a Peptide of Single Point-Mutated, Oncogenic Ras Proteins", pages 273-276, see entire document.	1-50
Y	SCIENCE, Volume 250, issued 05 October 1990, O. Halevy et al, "Different Tumor-Derived p53 Mutants Exhibit Distinct Biological Activities", pages 113-116, see entire document.	26-50
Y	SCIENCE, Volume 249, issued 24 August 1990, S.J. Baker et al, "Suppression of Human Colorectal Carcinoma Cell Growth by Wild-Type p53", pages 912-915, see entire document.	26-50

**B. FIELDS SEARCHED**

Electronic data bases consulted (Name of data base and where practicable terms used):

USPAT, EMBASE, CA, MEDLINE, INVESTEXT, HEALTH PERIODICALS DATABASE, PTS NEWSLETTER, HEALTH NEWS DAILY, PTS PROMT, DIALOG

SEARCH TERMS: LEVINE, P53, VACCI?, IMMUNIZ?, TREAT?, THERAP?, WILD TYPE, MUTANT, DENDRITIC, MONOCTYE, ANTIGEN PRESENTING CELL, RECOMBINANT, BCG, BACILL? CALMETTE GURIN